Angio Edema Clinical Trial
Official title:
Evaluation of New Markers (FXII and Videocapillaroscopy) in Type 3 Angioedema
Angioedema is a common condition, with multiple etiologies.
Type 3 angioedema is caused by an increase in kininogenase activity responsible for an
increased production of bradykinin. In some cases, it may be associated with clotting factor
12 mutations. However, other genetic abnormalities remain to be identified.
Clinically, this angioedema type 3 is similar to types 1 and 2. The patient's vital prognosis
is good if the diagnosis is made and if they have access to the appropriate treatment.
Otherwise a significant morbidity is associated with it, hence the importance of being able
to define a diagnostic marker.
Videocapillaroscopy might be able to highlight abnormalities in the microcirculation of
patients with a clinical display of angioedema.
The purpose of this study is to highlight markers allowing to make an early diagnosis of
angioedema. Functional analysis of factor XII in patients with symptoms of angioedema may be
an interesting marker for diagnosis.
Microcirculation abnormalities will also be evaluated by videocapillaroscopy, which may be
another indicator of the disease.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04963634 -
Research of Biomarkers Associated With the Diagnosis and Severity of Bradykinin Angioedema
|
||
| Completed |
NCT03029728 -
Biomarker for Hereditary AngioEdema Disease
|